CJ 바이오사이언스

311690KOSDAQ

51.3 / 100

Reference Date: 2026-09-08

Financial Score18.5 / 40

News Sentiment18.8 / 25

Momentum7.0 / 20

Disclosure7.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Rose 6.9% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

CJ BioScience operates core businesses including AI-powered microbiome analysis platforms (Ez-Mx®) for drug development, microbial genome analysis solutions, and health & wellness services (e.g., GUT INSIDE, SMILE GUT). The company has strategically shifted focus toward health & wellness, expanding consumer-accessible AI-based gut health diagnostic services in 2025. The majority of revenue comes from its microbiome genome analysis platform, EzBioCloud.

Number of Employees

102people

Average Salary

79.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

0.98Industry Average 1.204.0Point

In line with industry avg

ROE

-36.54Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

7.72Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20252.5 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼15.7% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲10.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -39.5% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 75

Positive
이너프유, CJ바이오사이언스 등과 '영유아 장 케어' 프로그램 운영
이너프유와 CJ바이오사이언스의 협력으로 영유아 장 건강 프로그램 출시, 긍정적인 건강 관리 트렌드 반영.

Detailed Momentum

52-week position1.0Point

Near 52w low (11%, downtrend)

Current 4,020Won52-week high 10,21052-week low 3,185

1-month return4.0Point

1m +6.91% (slight rise)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 2Negative 1

Neutral대규모기업집단현황공시[분기별공시(개별회사용)]2026-08-28
Negative지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항2026-08-14
Neutral반기보고서 (2026.06)2026-08-14